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Purpose of the study
The PREDICT-1 study has recently proven the clinical util-
ity of prospective genetic screening of HLA-B*5701 to
reduce the incidence of abacavir hypersensitivity reactions
(ABC HSR). Here we report an observational study that
aimed to describe the clinical management and adverse
events in HLA-B*5701 positive subjects excluded from
PREDICT-1. We evaluate the clinical outcome of these
subjects, specifically the choice of ART and resulting
adverse events, to explore how clinicians use pharmacoge-
netic information to guide practice.
Methods
Subjects who were enrolled into PREDICT-1 but withdrew
before start of study treatment due to a positive HLA-
B*5701 screening result, were consented for further fol-
low-up. PREDICT-1 patients could be ART naive or expe-
rienced, but were abacavir naïve. Patients in this study
were followed for a 6-week observation period following
treatment initiation or switch, or decision not to change
the current therapy, based on the notification of the HLA-
B*5701 status.
Summary of results
55 subjects withdrew from PREDICT-1 with a positive
HLA-B*5701 result; 32/55 patients consented to partici-
pate in this study. An additional three subjects were
enrolled in the UK under a country-specific protocol
amendment of PREDICT-1, and are also included in this
analysis. Baseline demographics were similar to the PRE-
DICT-1 study population, except for race where a greater
proportion of the study population was white. 32/35
patients received ART during the observation period. The
most common NRTIs were TDF/FTC (12) and AZT/3TC
(11); the most common third drugs were EFV (13) and
KAL (six). Seven subjects initiated ART and seven subjects
changed their ART regimen following notification of a
positive HLA-B*5701 result; 22 subjects did not change
ART during the observation period. One subject mistak-
enly received abacavir-containing therapy for 9 days prior
to awareness of their HLA-B*5701 status, but did not suf-
fer an ABC HSR during this time. Four subjects reported
AEs (Grade 1 or 2 only). Two subjects experienced AEs
that were related to current treatment, one leading to dis-
continuation of Combivir.
Conclusion
HLA-B*5701 positive patients and their clinicians chose
treatment options that actively avoided exposure to
abacavir. Mistakes can happen, highlighting the need for
accurate reporting of screening results. Physicians and
patients accept pharmacogenetic screening, and use the
result to guide patient management, showing that phar-
macogenetic screening allows for personalisation of ther-
apy.
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